标题
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
作者
关键词
-
出版物
CEPHALALGIA
Volume 38, Issue 6, Pages 1026-1037
出版商
SAGE Publications
发表日期
2018-02-23
DOI
10.1177/0333102418759786
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary
- (2017) Ariane K. Kawata et al. HEADACHE
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
- (2016) David W. Dodick et al. HEADACHE
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Improving Medication Adherence in Migraine Treatment
- (2015) Elizabeth K. Seng et al. Current Pain and Headache Reports
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
- (2014) C Xu et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
- (2014) T. W. Ho et al. NEUROLOGY
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men
- (2010) Bart J. Van der Schueren et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Current practice and future directions in the prevention and acute management of migraine
- (2010) Peter J Goadsby et al. LANCET NEUROLOGY
- CGRP and its receptors provide new insights into migraine pathophysiology
- (2010) Tony W. Ho et al. Nature Reviews Neurology
- Analysis of Safety and Tolerability Data Obtained from Over 1,500 Patients Receiving Topiramate for Migraine Prevention in Controlled Trials
- (2008) James Adelman et al. PAIN MEDICINE
- Placebo response in the prophylaxis of migraine: A meta-analysis
- (2007) Ana Macedo et al. EUROPEAN JOURNAL OF PAIN
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started